Bayer Acquires Perfuse Therapeutics for $2.45 Billion to Advance Novel Glaucoma and Diabetic Retinopathy Treatment
核心洞察
Bayer (搜索) announced the acquisition of Perfuse Therapeutics (搜索) for up to $2.45 billion, marking its largest deal since the 2020 AskBio acquisition.
The acquisition centers on PER-001, a small molecule endothelin receptor (搜索) antagonist in Phase II trials for glaucoma (搜索) and diabetic retinopathy (搜索) treatment.
PER-001 represents one of the first potential disease-modifying treatments for both conditions, targeting visual field improvement in glaucoma (搜索) and contrast sensitivity enhancement in diabetic retinopathy (搜索).
Bayer (搜索) has agreed to acquire Perfuse Therapeutics (搜索) for up to $2.45 billion, securing rights to a promising experimental treatment for glaucoma (搜索) and diabetic retinopathy (搜索) that could become one of the first disease-modifying therapies for these leading causes of blindness. The German pharmaceutical giant announced the deal on May 6, 2026, marking its largest acquisition since the $4 billion AskBio purchase in 2020.
Novel Mechanism Targets Endothelin Pathway
The acquisition centers on PER-001, an investigational small molecule endothelin receptor (搜索) antagonist currently in Phase II clinical development. The drug targets endothelin, described as "the most potent vasoconstrictor in the human body," which becomes upregulated in glaucoma (搜索), diabetic retinopathy (搜索), age-related macular degeneration, and retinal vein occlusion.
PER-001 is formulated as an intravitreal implant—a bio-erodible device administered into the vitreous cavity using a single-use, 25-gauge applicator. The sustained-release platform is designed to provide convenient dosing while delivering therapeutic levels of the drug directly to affected retinal tissues.
Addressing Significant Unmet Medical Need
Glaucoma (搜索) affects approximately 76-80 million people worldwide as of 2020, with projections indicating this number will reach 112 million by 2040 due to population aging. As the leading cause of irreversible vision loss, glaucoma represents a progressive optic neuropathy causing retinal ganglion cell loss and visual field deterioration. Despite its prevalence, no approved treatments currently exist that can prevent disease progression independently of lowering intraocular pressure.
Diabetic retinopathy (搜索) presents an equally compelling medical need, affecting about 146 million people globally—approximately 25 percent of adults with diabetes. This microvascular complication damages retinal capillaries, causing ischemia, leakage, and neovascularization. The condition is projected to affect 160 million people by 2045, with 25 million currently experiencing vision-threatening disease and 1.3 million people already blind from the condition.
Strategic Expansion of Ophthalmology Portfolio
The acquisition complements Bayer (搜索)'s existing ophthalmology expertise, particularly as the company faces patent expiration challenges with Eylea, its top-selling pharmaceutical product in 2025. Eylea now confronts pricing pressures following patent loss, making the Perfuse acquisition strategically important for pipeline reinforcement.
"We are excited by the work of the team at Perfuse Therapeutics (搜索) and encouraged by the potential of PER-001," said Juergen Eckhardt, M.D., Head of Business Development and Licensing at Bayer (搜索) Pharmaceuticals. "With this acquisition, we are complementing our expertise in ophthalmology and our pipeline, reinforcing our commitment to developing urgently needed therapies for patients."
Deal Structure and Financial Terms
Under the agreement terms, Bayer (搜索) will pay $300 million upfront, with the remaining $2.15 billion contingent on achieving development, regulatory, and commercial milestones. The transaction requires antitrust clearances and Perfuse stockholder approvals before completion.
Sevgi Gurkan, MD, Founder and CEO of Perfuse Therapeutics (搜索), expressed confidence in the partnership: "Bayer (搜索)'s vision aligns closely with ours, and they have the scale and global resources to unlock the full potential of PER-001 to change the trajectory of human blindness."
Return to Strategic Acquisitions
This acquisition represents Bayer (搜索)'s return to significant dealmaking after years of debt reduction following the $63 billion Monsanto acquisition in 2018. The company had largely avoided major transactions while focusing on cost reduction and operational streamlining, though it completed smaller acquisitions including Vividion Therapeutics for up to $2 billion and KaNDy Therapeutics for up to $875 million.
Stefan Oelrich, Bayer (搜索)'s pharma head, had indicated in recent interviews that the company was actively negotiating multiple deals, suggesting this acquisition may signal renewed strategic expansion in the pharmaceutical sector.